Navigation Links
Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies
Date:5/14/2015

INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.

The comprehensive research collaboration is driven by Lilly's world-class biotechnology capabilities and expertise in immunology, and Sanford-Burnham's deep expertise in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F. Bumol, Ph.D., senior vice president, biotechnology and immunology research at Lilly, and Carl Ware, Ph.D., director, Infectious and Inflammatory Diseases Center at Sanford-Burnham.

"Immunology is an important research area of focus for Lilly, and through this exciting collaboration with Sanford-Burnham, our scientists can discover and develop new medicines together in a seamless way that takes advantage of each group in a family of key targets," said Bumol.

Lilly has established its presence in immunology in recent years through its own R&D and collaborations, with seven molecules currently in the pipeline for conditions such as psoriasis, rheumatoid arthritis, lupus and inflammatory bowel disease. Sanford-Burnham's work in this area focuses on cell communication pathways that control the development of lymphocytes, innate and adaptive immune responses, and inflammation. Their work has led to the discovery of molecular targets for the development of treatments for immunological and inflammatory diseases, and cancer.

"The Lilly-Sanford-Burnham collaboration is precedent setting in scope and its potential to advance discoveries to the patient more efficiently," said Sanford-Burnham CEO Perry Nisen, M.D., Ph.D. "By combining the deep knowledge of human biology and disease mechanisms among Sanford-Burnham scientists, in particular our expertise in the field of checkpoint regulators in the immune system, and Lilly's leadership position in the development of biologics and large molecules, we are forging the path to develop the next generation of transformative treatments for autoimmune disease."

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. (C-LLY)

About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center, its NIH-designated Neuroscience Center Cores, and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at sanfordburnham.org. Sanford-Burnham can also be found on Facebook at facebook.com/sanfordburnham and on Twitter @sanfordburnham.

This press release contains forward-looking statements about the preclinical collaboration between Sanford-Burnham Medical Research Institute and Lilly and reflects Lilly's current beliefs. However, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. There is no guarantee that the collaboration will yield successful results or that either company will achieve the anticipated benefits. For further discussion of these and other risks and uncertainties, see Lilly's most recent 10-K and 10-Q filings with the United States Securities and Exchange Commission. Except as may be required by law, Lilly undertakes no duty to update forward-looking statements to reflect events occurring after the date of this release.

Refer to: Amy Sousa; sousa_amy_e@lilly.com; 317.997.1481; Eli Lilly and Company            Deborah Robison; drobison@sanfordburnham.org; 407.745.2073;
Sanford-Burnham Medical Research Institute

 

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

Logo - http://photos.prnewswire.com/prnh/20150512/215499LOGO


'/>"/>
SOURCE Eli Lilly and Company; Sanford-Burnham Medical Research Institute
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016
2. Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies
3. Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts
4. Lilly Declares Second-Quarter 2015 Dividend
5. Lilly Releases Corporate Responsibility, Global Health Reports
6. Lillys Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis
7. Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement
8. Lilly Announces Date for Diabetes Investor Meeting
9. Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
10. Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy
11. German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2020)... ... September 02, 2020 , ... Rigaku Analytical Devices , ... among industry professionals about successes and challenges of making changes to their organizations’ ... and will take place on October 15, 2020 at 10:00am PDT / ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... Cosmetics and Laser Surgery at the University of Rochester Medical Center, in Upstate ... SkinCare Physicians in Boston, with clinical faculty from the Harvard and Yale Departments ...
(Date:9/1/2020)... ... ... September is National Ovarian Cancer Awareness Month. Ovarian cancer is the 5th deadliest ... reproductive system. The American Cancer Society estimates that in 2020, about 22,000 women ... disease. Throughout the month of September, Women’s Excellence aims to increase understanding of ...
Breaking Medicine Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... BluePearl Specialty and Emergency ... Prevention’s (AFSP) annual signature event, Out of the Darkness (OOTD), which unites more ... raise awareness of suicide prevention. To ensure Associate safety, BluePearl will not be ...
(Date:9/2/2020)... FORT WASHINGTON, Pa. (PRWEB) , ... September 02, ... ... the development of enterprise software for healthcare payers administering Medicare Advantage and Special ... and Duals Online presented by America’s Health Insurance Plans (AHIP). RAM is supporting ...
(Date:9/1/2020)... NAPLES, Fla. (PRWEB) , ... September 01, 2020 ... ... and Reconstructive Surgeon with specialty fellowship training in aesthetic surgery of the face, ... Gill, MD – the only female-owned premier boutique plastic surgery and aesthetic practice ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... Want to ... 1, Cerebral Palsy Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual ... research. A fully virtual challenge, STEPtember meets everyone wherever they are at this moment ...
(Date:8/31/2020)... ... 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At this ... state of panic, experiencing deep anxiety, immense stress, and right now are needing serious relief ... most people on the planet are experiencing a great degree of emotional discomfort, be it ...
Breaking Medicine News(10 mins):